三利譜(002876.SZ):上半年淨利同比增長22.64倍至2875.05萬元
格隆匯8月25日丨三利譜(002876.SZ)披露2020年半年度報告,報告期內,公司實現營業收入7.72億元,同比上漲25.21%;實現利潤總額3786.21萬元,同比上漲398.67%;實現歸屬於上市公司股東的淨利潤為2875.05萬元,同比上漲2264.09%,扣除非經常性損益後歸屬於母公司的淨利潤為1837.62萬元,同比上漲394.87%。
報告期內,歸屬於上市公司股東的淨利潤較上年同期有較大幅度增長,主要原因是子公司合肥三利譜光電產能利用率大幅提升致營業收入大幅增長,相應單位成本下降,逐漸達到盈虧平衡點;同時公司依據年度預算,嚴控期間費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.